Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Neurodon

Neurodon
PRIVATE STATUS
Angel LATEST DEAL TYPE
$500K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of a new healthcare technology intended to provide effective way to treat Parkinson's disease. The company novel strategy focuses halting the process of endoplasmic reticulum stress, which is a major cause of the disease, providing healthcare professionals with new technology and medicines that can effectively cure Parkinson's disease as well as Alzheimer's disease and Huntington's disease.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 9800 Conneticuit Drive
  • Crown Point, IN 46307
  • United States

+1 (219) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Neurodon’s full profile, request a free trial.

Neurodon Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 17-Oct-2019 $500K 00000 Completed Startup
1. Grant 01-Jan-2018 00000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Neurodon Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
U.S. Department of Health and Human Services Government 000 0000 000000 0

Neurodon Executive Team (1)

Name Title Board
Seat
Contact
Info
Russell Dahl Ph.D Founder, Board Member & Chief Executive Officer

Neurodon Board Members (1)

Name Representing Role Since Contact
Info
Russell Dahl Ph.D Neurodon Founder, Board Member & Chief Executive Officer 000 0000